OVERWATCH WELLNESS SIDE-BY-SIDE
Compare Compounds
Compare mechanism, research focus, evidence strength, half-life context, and related Overwatch Wellness profiles without treating different compounds as interchangeable.
Clickable evidence tiersMechanism-first comparisonsEvidence limitations shown
Retatrutide vs. metabolic compoundsTriple agonism, mitochondrial signaling, and NNMT biologyGHK-Cu vs. AHK-CuSkin, hair, matrix, and copper-peptide evidenceTesamorelin vs. CJC/IpamorelinGHRH analog versus dual secretagogue researchMOTS-c vs. NAD+Peptide signaling versus cellular coenzyme biology
| Compound | Class / mechanism | Primary focus | Evidence | Half-life context | Explore |
|---|---|---|---|---|---|
| Retatrutide | Triple GLP-1/GIP/glucagon receptor agonist | Body composition, Appetite regulation | Approximately six days in published clinical pharmacology reports | Full profile | |
| KLOW | Lot-specific blend: GHK-Cu, KPV, BPC-157, and thymosin beta-4 fragments | Tissue-repair research, Inflammatory signaling | No single half-life applies because KLOW contains multiple components with different pharmacokinetics | Full profile | |
| CJC-1295 / Ipamorelin | GHRH analog plus ghrelin-receptor agonist | Growth-hormone pulsatility, IGF-1 signaling | Depends on the CJC-1295 form; DAC and non-DAC versions should never be treated as interchangeable | Full profile | |
| Tesamorelin | Stabilized growth-hormone-releasing hormone analog | Visceral adipose tissue, Growth-hormone axis | Short plasma half-life with downstream hormonal effects lasting longer than measurable parent compound | Full profile | |
| Wolverine | Two-compound repair-research blend | Tendon and ligament models, Angiogenesis research | No validated human blend half-life; component estimates vary and should not be treated as a clinical schedule | Full profile | |
| MOTS-c | Mitochondrial-derived peptide encoded within mitochondrial DNA | Mitochondrial signaling, Insulin sensitivity | Reliable human pharmacokinetic estimates remain limited | Full profile | |
| NAD+ | Nicotinamide adenine dinucleotide coenzyme | Cellular energy, Redox reactions | Highly context-dependent because NAD+ is rapidly used and compartmentalized within cells | Full profile | |
| GHK-Cu | Copper-binding tripeptide | Collagen and elastin, Wound repair | No single clinically established half-life across topical and injectable research contexts | Full profile | |
| AHK-Cu | Copper-binding tripeptide analog | Dermal papilla cells, Hair-follicle biology | No well-established human pharmacokinetic value for cosmetic use | Full profile | |
| 5-Amino-1MQ | Small-molecule nicotinamide N-methyltransferase inhibitor | Adipose-tissue metabolism, NAD+ pathways | Reliable human pharmacokinetic data are not established | Full profile | |
| Lemon Bottle | Commercial cosmetic injectable formulation | Localized body-contouring claims, Cosmetic formulation | Not established as a single active pharmaceutical ingredient | Full profile |